Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2023 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit

DOYLESTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
January 11, 2023 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors

DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
November 09, 2022 16:15 ET | Source: Aprea Therapeutics

Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...
September 22, 2022 18:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
September 08, 2022 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference

BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
August 11, 2022 16:15 ET | Source: Aprea Therapeutics

Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...
August 02, 2022 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference

BOSTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting...
May 16, 2022 09:21 ET | Source: Aprea Therapeutics

Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage...
March 15, 2022 16:15 ET | Source: Aprea Therapeutics

Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
January 06, 2022 08:00 ET | Source: Aprea Therapeutics

Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right